Cytoo secures financing
Grenoble – French specialists in high content screening (HCS), Cytoo SA, have secured EUR3m in a second funding round led by its new investor Auriga Partners. The one year old company said it will use the money to expand its business internationally, hire new staff, and to strengthen R&D. The start-up recently launched a micropatterned glass substrate called CYTOOchip™, which normalises cell architecture by fixing the cell in a specific manner on the glass substrate, thus reducing cell variability. The technology platform aims to improve cell-based assays, and has a wide range of biopharmaceutical applications, including cell signalling, cell adhesion and polarity, cell division, and precise protein colocalisation.